Top

Published in:

Open Access 01-11-2019 | Instillation Therapy | Topic Paper

Consultation on UTUC, Stockholm 2018: aspects of treatment

Authors: Helene Jung, Guido Giusti, Harun Fajkovic, Thomas Herrmann, Robert Jones, Michael Straub, Joyce Baard, Palle Jörn Sloth Osther, Marianne Brehmer

Published in: World Journal of Urology | Issue 11/2019

Abstract

Purpose

To provide an overview of treatment modalities for management of upper tract urothelial carcinoma (UTUC).

Methods

In accordance with the standards for a scoping review, data presentation and discussion at the Consultation on UTUC in Stockholm, 6–7 September 2018, consensus was reached on the latest and most important treatment recommendations for UTUC. Using Pubmed, Web of Science, and Embase, publications were selected based on quality, clinical relevance, and level of evidence.

Results

Kidney-sparing surgery should be attempted for low-grade UTUC. Radical nephroureterectomy with bladder cuff excision is first option for high-grade disease. Post-operative bladder instillation of chemotherapy should be offered after RNU to reduce intravesical recurrence rate. Identification of tumor grade and stage is crucial when selecting treatment. Ureteroscopic management of low-grade and non-invasive UTUC achieves disease-free survival similar to that offered by radical nephroureterectomy but seems to be a risk factor for intravesical recurrence. Lymphadenectomy appears important for high-risk disease, although the therapeutic benefit needs further validation. There is little evidence supporting use of Bacillus Calmette–Guérin (BCG) and mitomycin C as monotherapy and adjuvant treatment in UTUC. A randomized clinical trial has indicated that platin-based chemotherapy for invasive UTUC improves disease-free survival, suggesting that adjuvant chemotherapy should be considered standard care for ≥ T2 N0–3M0 disease.

Conclusions

Risk stratification assessment is feasible and mandatory in UTUC. Identification of tumor grade and stage is essential for optimal treatment selection. Kidney-sparing surgery should be offered in low-risk disease, whereas radical nephroureterectomy and adjuvant chemotherapy should be considered in high-risk disease.

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, Shariat SF (2018) European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73(1):111–122. https://doi.org/10.1016/j.eururo.2017.07.036 CrossRefPubMed

Elawdy MM, Taha DE, Elbaset MA, Abouelkheir RT, Osman Y (2016) Histopathologic characteristics of upper tract urothelial carcinoma with an emphasis on their effect on cancer survival: a single-institute experience with 305 patients with long-term follow-up. Clin Genitourin Cancer 14(6):e609–e615. https://doi.org/10.1016/j.clgc.2016.04.017 CrossRefPubMed

Villa L, Haddad M, Capitanio U, Somani BK, Cloutier J, Doizi S, Salonia A, Briganti A, Montorsi F, Traxer O (2018) Which patients with upper tract urothelial carcinoma can be safely treated with flexible ureteroscopy with holmium:YAG laser photoablation? Long-term results from a high volume institution. J Urol 199(1):66–73. https://doi.org/10.1016/j.juro.2017.07.088 CrossRefPubMed

Grasso M, Fishman AI, Cohen J, Alexander B (2012) Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int 110(11):1618–1626. https://doi.org/10.1111/j.1464-410X.2012.11066.x CrossRefPubMed

Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA (2012) Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 110(5):614–628. https://doi.org/10.1111/j.1464-410X.2012.11068.x CrossRefPubMed

Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH (2012) High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology 79(3):615–619. https://doi.org/10.1016/j.urology.2011.11.049 CrossRefPubMed

Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vijay V, Silver H, Clinton TN, Krabbe LM, Woldu SL, Singla N, Bagrodia A, Margulis V, Huang WC, Bjurlin MA, Shah O, Anderson CB (2018) Discordance between ureteroscopic biopsy and final pathology for upper tract urothelial carcinoma. J Urol 199(6):1440–1445. https://doi.org/10.1016/j.juro.2018.02.002 CrossRefPubMed

Vemana G, Kim EH, Bhayani SB, Vetter JM, Strope SA (2016) Survival comparison between endoscopic and surgical management for patients with upper tract urothelial cancer: a matched propensity score analysis using surveillance, epidemiology and end results-medicare data. Urology 95:115–120. https://doi.org/10.1016/j.urology.2016.05.033 CrossRefPubMed

Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Bohle A, Burger M, Comperat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Roupret M (2016) Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 70(6):1052–1068. https://doi.org/10.1016/j.eururo.2016.07.014 CrossRefPubMed

10.

USRDS (2010) United States renal data system 2010 annual data report. Atlas of chronic kidney disease and end-stage renal disease in the United States, Bethesda, MA (2010). National institutes of health, national institute of diabetes and digestive and kidney diseases

11.

Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, Yossepowitch O, Coleman J, Traxer O, Anderson JK, Catto J, de la Rosette J, O’Brien T, Zlotta A, Matin SF (2017) Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol 35(3):355–365. https://doi.org/10.1007/s00345-016-1859-6 CrossRefPubMed

12.

Tada Y, Yokomizo A, Koga H, Seki N, Kuroiwa K, Tatsugami K, Yamaguchi A, Naito S (2010) Transurethral endoscopic treatment of patients with upper tract urothelial carcinomas using neodymium-YAG and/or holmium-YAG laser ablation. BJU Int 106(3):362–366. https://doi.org/10.1111/j.1464-410X.2009.09131.x CrossRefPubMed

13.

Cutress ML, Stewart GD, Tudor EC, Egong EA, Wells-Cole S, Phipps S, Thomas BG, Riddick AC, McNeill SA, Tolley DA (2013) Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience. J Urol 189(6):2054–2060. https://doi.org/10.1016/j.juro.2012.12.006 CrossRefPubMed

14.

Villa L, Cloutier J, Letendre J, Ploumidis A, Salonia A, Cornu JN, Montorsi F, Traxer O (2016) Early repeated ureteroscopy within 6–8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol 34(9):1201–1206. https://doi.org/10.1007/s00345-015-1753-7 CrossRefPubMed

15.

Guo RQ, Hong P, Xiong GY, Zhang L, Fang D, Li XS, Zhang K, Zhou LQ (2018) Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int 121(2):184–193. https://doi.org/10.1111/bju.14053 CrossRefPubMed

16.

Musi G, Mistretta FA, Marenghi C, Russo A, Catellani M, Nazzani S, Conti A, Luzzago S, Ferro M, Matei DV, Carmignani L, de Cobelli O (2018) Thulium laser treatment of upper urinary tract carcinoma: a multi-institutional analysis of surgical and oncological outcomes. J Endourol 32(3):257–263. https://doi.org/10.1089/end.2017.0915 CrossRefPubMed

17.

Furuse H, Matsushita Y, Yajima T, Kato T, Suzuki T, Matsumoto R, Motoyama D, Sugiyama T, Otsuka A, Ozono S (2017) Systematic regional lymph node dissection for upper tract urothelial carcinoma improves patient survival. Jpn J Clin Oncol 47(3):239–246. https://doi.org/10.1093/jjco/hyw179 CrossRefPubMed

18.

Fang D, Seisen T, Yang K, Liu P, Fan X, Singla N, Xiong G, Zhang L, Li X, Zhou L (2016) A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 42(11):1625–1635. https://doi.org/10.1016/j.ejso.2016.08.008 CrossRefPubMedPubMedCentral

19.

Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martinez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61(4):818–825. https://doi.org/10.1016/j.eururo.2012.01.021 CrossRefPubMed

20.

Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116(12):2967–2973. https://doi.org/10.1002/cncr.25043 CrossRefPubMed

21.

Matin SF, Gill IS (2005) Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control. J Urol 173(2):395–400. https://doi.org/10.1097/01.ju.0000148851.68215.93 CrossRefPubMed

22.

Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, Shariat SF, Upper Tract Urothelial Carcinoma C (2014) Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 65(1):210–217. https://doi.org/10.1016/j.eururo.2012.04.052 CrossRefPubMed

23.

Favaretto RL, Shariat SF, Chade DC, Godoy G, Kaag M, Cronin AM, Bochner BH, Coleman J, Dalbagni G (2010) Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol 58(5):645–651. https://doi.org/10.1016/j.eururo.2010.08.005 CrossRefPubMedPubMedCentral

24.

Walton TJ, Novara G, Matsumoto K, Kassouf W, Fritsche HM, Artibani W, Bastian PJ, Martinez-Salamanca JI, Seitz C, Thomas SA, Ficarra V, Burger M, Tritschler S, Karakiewicz PI, Shariat SF (2011) Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 108(3):406–412. https://doi.org/10.1111/j.1464-410X.2010.09826.x CrossRefPubMed

25.

Greco F, Wagner S, Hoda RM, Hamza A, Fornara P (2009) Laparoscopic vs open radical nephroureterectomy for upper urinary tract urothelial cancer: oncological outcomes and 5-year follow-up. BJU Int 104(9):1274–1278. https://doi.org/10.1111/j.1464-410X.2009.08594.x CrossRefPubMed

26.

Simone G, Papalia R, Guaglianone S, Ferriero M, Leonardo C, Forastiere E, Gallucci M (2009) Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol 56(3):520–526. https://doi.org/10.1016/j.eururo.2009.06.013 CrossRefPubMed

27.

Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, Maclennan S, N’Dow J, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Mostafid H, van Rhijn BWG, Gontero P, Palou J, Shariat SF, Roupret M (2017) Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology guidelines systematic review. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.10.003 CrossRefPubMed

28.

Moschini M, Foerster B, Abufaraj M, Soria F, Seisen T, Roupret M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chlosta P, Bandini M, Montorsi F, Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, Briganti A, Shariat SF (2017) Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 35(10):1541–1547. https://doi.org/10.1007/s00345-017-2026-4 CrossRefPubMed

29.

Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernandez MI, Mikami S, Isida M, Michel MS, Montorsi F (2009) Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 181(6):2482–2489. https://doi.org/10.1016/j.juro.2009.02.021 CrossRefPubMed

30.

Kondo T, Hara I, Takagi T, Kodama Y, Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Yoshida K, Tanabe K (2014) Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol 21(5):453–459. https://doi.org/10.1111/iju.12417 CrossRefPubMed

31.

Suttmann H, Kamradt J, Lehmann J, Stockle M (2007) Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection. BJU Int 100(6):1221–1224. https://doi.org/10.1111/j.1464-410x.2007.07114.x CrossRefPubMed

32.

Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kalble T, Stockle M, Schnoller T, Stenzl A, Muller M, Truss M, Roth S, Liehr UB, Leissner J, Bregenzer T, Retz M (2018) Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol. https://doi.org/10.1016/j.eururo.2018.09.047 CrossRefPubMed

33.

Marits P, Karlsson M, Sherif A, Garske U, Thorn M, Winqvist O (2006) Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 49(1):59–70. https://doi.org/10.1016/j.eururo.2005.09.010 CrossRefPubMed

34.

Krantz D, Hartana CA, Winerdal ME, Johansson M, Alamdari F, Jakubczyk T, Huge Y, Aljabery F, Palmqvist K, Zirakzadeh AA, Holmstrom B, Riklund K, Sherif A, Winqvist O (2018) Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder cancer. Eur Urol 74(6):688–692. https://doi.org/10.1016/j.eururo.2018.06.048 CrossRefPubMed

35.

Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K (2007) Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 178(4 Pt 1):1212–1217. https://doi.org/10.1016/j.juro.2007.05.158 (discussion 1217) CrossRefPubMed

36.

Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Fernandez MI, Mikami S, Isida M, Strobel P, Montorsi F (2009) The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 56(3):512–518. https://doi.org/10.1016/j.eururo.2009.06.004 CrossRefPubMed

37.

Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H, Ito F, Tanabe K (2010) Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol 17(10):848–854. https://doi.org/10.1111/j.1442-2042.2010.02610.x CrossRefPubMed

38.

Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ (2013) Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int 91(3):291–296. https://doi.org/10.1159/000350508 CrossRefPubMed

39.

Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y (2013) Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 31(11):1422–1427. https://doi.org/10.1200/JCO.2012.45.2128 CrossRefPubMed

40.

O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of O (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60(4):703–710. https://doi.org/10.1016/j.eururo.2011.05.064 CrossRefPubMed

41.

Keeley FX Jr, Bibbo M, Bagley DH (1997) Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 157(5):1560–1565CrossRefPubMed

42.

Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF (2017) Upper urinary tract carcinoma in situ: current knowledge, future direction. J Urol 197(2):287–295. https://doi.org/10.1016/j.juro.2016.03.194 CrossRefPubMed

43.

Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE (2011) Antegrade perfusion with Bacillus Calmette–Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 60(5):955–960. https://doi.org/10.1016/j.eururo.2011.07.051 CrossRefPubMed

44.

Liu Z, Ng J, Yuwono A, Lu Y, Tan YK (2017) Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods. Int Braz J Urol 43(6):1084–1091. https://doi.org/10.1590/S1677-5538.IBJU.2016.0258 CrossRefPubMedPubMedCentral

45.

Pollard ME, Levinson AW, Shapiro EY, Cha DY, Small AC, Mohamed NE, Badani KK, Gupta M (2013) Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model. Urology 82(6):1451–1456. https://doi.org/10.1016/j.urology.2013.08.048 CrossRefPubMed

46.

Jung H, Norby B, Frimodt-Moller PC, Osther PJ (2008) Endoluminal isoproterenol irrigation decreases renal pelvic pressure during flexible ureterorenoscopy: a clinical randomized, controlled study. Eur Urol 54(6):1404–1413. https://doi.org/10.1016/j.eururo.2008.03.092 CrossRefPubMed

47.

Jung H, Osther PJ (2015) Intraluminal pressure profiles during flexible ureterorenoscopy. SpringerPlus 4:373. https://doi.org/10.1186/s40064-015-1114-4 CrossRefPubMedPubMedCentral

48.

Knoedler JJ, Raman JD (2018) Intracavitary therapies for upper tract urothelial carcinoma. Expert Rev Clin Pharmacol 11(5):487–493. https://doi.org/10.1080/17512433.2018.1461560 CrossRefPubMed

49.

Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF (2017) Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes. J Endourol 31(9):946–953. https://doi.org/10.1089/end.2016.0871 CrossRefPubMedPubMedCentral

50.

Lifshitz D (2014) Hydrogel based drug retention system for the treatment of upper tract urothelial carcinoma. Eur Urol Suppl 13(1):e25CrossRef

51.

Barros AA, Browne S, Oliveira C, Lima E, Duarte AR, Healy KE, Reis RL (2016) Drug-eluting biodegradable ureteral stent: new approach for urothelial tumors of upper urinary tract cancer. Int J Pharm 513(1–2):227–237. https://doi.org/10.1016/j.ijpharm.2016.08.061 CrossRefPubMed

52.

Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P (2018) Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag 14:1019–1040. https://doi.org/10.2147/TCRM.S158753 CrossRefPubMedPubMedCentral

53.

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Duran I, Theodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS (2017) Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens. Eur Urol. https://doi.org/10.1016/j.eururo.2017.11.023 CrossRefPubMedPubMedCentral

54.

Moschini M, Shariat SF, Roupret M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L (2018) Impact of primary tumor location on survival from the European Organization for the research and treatment of cancer advanced urothelial cancer studies. J Urol 199(5):1149–1157. https://doi.org/10.1016/j.juro.2017.11.068 CrossRefPubMed

55.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, Investigators K (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683 CrossRefPubMedPubMedCentral

56.

Kwak C, Lee SE, Jeong IG, Ku JH (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68(1):53–57. https://doi.org/10.1016/j.urology.2006.01.053 CrossRefPubMed

57.

Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat SF, European Association of Urology-Young Academic Urologists UCG, the Upper Tract Urothelial Carcinoma Collaboration G (2018) Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 121(2):252–259. https://doi.org/10.1111/bju.14020 CrossRefPubMed

58.

Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Roupret M, Leow JJ, Vetterlein MW, Sun M, Alanee S, Choueiri TK, Trinh QD, Menon M, Abdollah F (2017) Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma. Eur Urol 71(5):714–718. https://doi.org/10.1016/j.eururo.2016.11.012 CrossRefPubMed

59.

Kubota Y, Hatakeyama S, Tanaka T, Fujita N, Iwamura H, Mikami J, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Sasaki A, Kawaguchi T, Ohyama C (2017) Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 8(60):101500–101508. https://doi.org/10.18632/oncotarget.21551 CrossRefPubMedPubMedCentral

60.

Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794–1799. https://doi.org/10.1002/cncr.28655 CrossRefPubMed

61.

Hosogoe S, Hatakeyama S, Kusaka A, Hamano I, Iwamura H, Fujita N, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ohyama C (2018) Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 4(6):946–953. https://doi.org/10.1016/j.euf.2017.03.013 CrossRefPubMed

Title: Consultation on UTUC, Stockholm 2018: aspects of treatment
Authors: Helene Jung
Guido Giusti
Harun Fajkovic
Thomas Herrmann
Robert Jones
Michael Straub
Joyce Baard
Palle Jörn Sloth Osther
Marianne Brehmer
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keywords: Instillation Therapy
Cytostatic Therapy
Urothelial Cancer
Urothelial Cancer
Published in: World Journal of Urology / Issue 11/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02811-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Consultation on UTUC, Stockholm 2018: aspects of treatment

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy

Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects

Predicting invasiveness and disease-specific survival in upper tract urothelial carcinoma: identifying relevant clinical tumour characteristics

Socioeconomic and patient-related factors for the management of male urethral stricture disease

Re: A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills? From Slaoui et al., World J urol 2019. Long-term safety of local radiation therapy of newly diagnosed low burden metastatic prostate cancer: an unaddressed concern

Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group)